The board of directors of SSY Group Limited announced that the Group's Benserazide hydrochloride has obtained the approval for registration from the National Medical Products Administration of China to become a bulk drug for the preparations on the market. Berazide hydrochloride is a decarboxylase inhibitor, which is mainly used in combination with Levodopa for the treatment of Parkinson's disease.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.78 HKD | +1.70% | -0.21% | -3.24% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-3.24% | 1.82B | |
+26.08% | 662B | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
+8.08% | 167B |
- Stock Market
- Equities
- 2005 Stock
- News SSY Group Limited
- SSY Group Limited Announces Update on Product Development